Mobility in Atypical Parkinsonism: a Trial of Physiotherapy (NCT04608604) | Clinical Trial Compass
CompletedNot Applicable
Mobility in Atypical Parkinsonism: a Trial of Physiotherapy
Austria180 participantsStarted 2021-02-01
Plain-language summary
Patients with atypical parkinsonism often show gait and mobility impairment manifesting in early disease stages.
In order to maintain mobility and physical autonomy as long as possible for these patients, we will examine the effect of two types of physiotherapy in patients with multiple system atrophy (MSA), progressive supranuclear gaze palsy (PSP) and idiopathic Parkinson's disease (IPD).
The study is divided into an ambulant daily in-patient physiotherapy phase, followed by a home-based training phase. At the beginning and the end of the study, the patients daily activity will be recorded for one week using Physical Activity Monitoring (PAM) sensors.
The aim of this double-blind, randomized-controlled study is to determine effective physiotherapy in patients with atypical parkinsonian syndromes in order to maintain mobility for as long as possible.
Who can participate
Age range30 Years – 80 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* The subject is willing and able to give written informed consent
* The patient is able to tolerate all study visits including daily physiotherapy and home training.
* Patients similar with regard to age and sex with probable/possible MSA-P according to rev. Gilman criteria OR probable/possible PSP-RS according to MDS-PSP criteria OR PD according to MDS-PD criteria.
* Stable antiparkinsonian and Anti-OH medication 4 weeks prior to study entry.
Exclusion Criteria:
* Co-morbidities that influence the clinical presentation of parkinsonian symptoms (as judged by the enrolling investigator).
* Participation in other clinical trials that might influence the impact of the trial intervention (as judged by the enrolling investigator)
* H\&Y Staging score greater than or equal to 4
* Change of antiparkinsonian and anti-OH medication 4 weeks prior to the interventional trial.
* Secondary cause of autonomic failure or parkinsonism (e.g. diabetic autonomic neuropathy, bladder surgery, drug-induced or vascular parkinsonism, etc.)
* Dementia according to DSM-V.